An Update on the Amyloid Hypothesis

Neurologic Clinics

Volumn 25, Issue 3, 2007, Pages 669-682

  Eckman, Christopher B ^a   Eckman, Elizabeth A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; CHROMOSOME 21; DOWN SYNDROME; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; HUMANS;

EID: 34447345415     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.03.007     Document Type: Review

References (79)

1. Wimo A., Jonsson L., and Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21 3 (2006) 175-181
2. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 8 (Aug 2003) 1119-1122
3. Markesbery W.R. Alzheimer's Disease. In: Asbury A.K., McKhann G.M., and McDonald W.I. (Eds). Diseases of the Nervous System: Clinical Neurobiology. 2 edition. Vol I (1992), W.B. Saunders Company, Philadelphia
4. Hardy J., and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12 10 (Oct 1991) 383-388
5. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 5054 (Apr 10 1992) 184-185
6. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 4 (Apr 1991) 487-498
7. Alzheimer A. Uber eine eigenartige, Erkrankung der Hirnrinde. Allg Z Psychiatrie Psychisch-Gerichtl Med 64 (1907) 146-148
8. Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Zbl Ges Neurol Psych 4 (1911) 356-385
9. Moller H.J., and Graeber M.B. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248 3 (1998) 111-122
10. Selkoe D.J. Cellular and molecular biology of the beta-amyloid precursor protein and Alzheimer's disease. In: Rosenberg R.N., Pruisner S.B., DiMauro S., and Barchi R.L. (Eds). The Molecular and Genetic Basis of Neurological Disease. 2 edition. (1997), Butterworth-Heinemann, Boston 601-611
11. Sipe J.D. Amyloidosis. Annu Rev Biochem 61 (1992) 947-975
12. Sipe J.D. Amyloidosis. Crit Rev Clin Lab Sci 31 4 (1994) 325-354
13. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120 3 (1984) 885-890
14. Mann D.M. Alzheimer's disease and Down's syndrome. Histopathology 13 2 (1988) 125-137
15. Glenner G.G., and Wong C.W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122 3 (1984) 1131-1135
16. Gorevic P.D., Goni F., Pons-Estel B., Alvarez F., Peress N.S., and Frangione B. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies. J Neuropathol Exp Neurol 45 6 (1986) 647-664
17. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82 12 (1985) 4245-4249
18. Kang J., Lemaire H.G., Unterbeck A., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325 6106 (1987) 733-736
19. Robakis N.K., Ramakrishna N., Wolfe G., and Wisniewski H.M. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. [published erratum appears in Proc Natl Acad Sci U S A 1987 Oct;84(20):7221]. Proc Natl Acad Sci U S A 84 12 (1987) 4190-4194
20. Tanzi R.E., Gusella J.F., Watkins P.C., et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235 4791 (1987) 880-884
21. Goldgaber D., Lerman M.I., McBride O.W., Saffiotti U., and Gajdusek D.C. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 235 4791 (1987) 877-880
22. Tokuda T., Fukushima T., Ikeda S., et al. Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. Ann Neurol 41 2 (1997) 271-273
23. Hardy J. Amyloid, the presenilins and Alzheimer's disease. [see comments]. Trends Neurosci 20 4 (1997) 154-159
24. Blacker D., and Tanzi R.E. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol 55 3 (1998) 294-296
25. Murrell J., Farlow M., Ghetti B., and Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254 5028 (1991) 97-99
26. Goate A., Chartier-Harlin M.C., Mullan M., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. [see comments]. Nature 349 6311 (1991) 704-706
27. Chartier-Harlin M.C., Crawford F., Houlden H., et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353 6347 (1991) 844-846
28. Mullan M., Crawford F., Axelman K., et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1 5 (1992) 345-347
29. Eckman C.B., Mehta N.D., Crook R., et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 6 12 (1997) 2087-2089
30. Sherrington R., Rogaev E.I., Liang Y., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. [see comments]. Nature 375 6534 (1995) 754-760
31. Levy-Lahad E., Wasco W., Poorkaj P., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. [see comments]. Science 269 5226 (1995) 973-977
32. Citron M., Oltersdorf T., Haass C., et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 360 6405 (1992) 672-674
33. Cai X.D., Golde T.E., and Younkin S.G. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. [see comments]. Science 259 5094 (1993) 514-516
34. Citron M., Vigo-Pelfrey C., Teplow D.B., et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci U S A 91 25 (1994) 11993-11997
35. Suzuki N., Cheung T.T., Cai X.D., et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264 5163 (1994) 1336-1340
36. Felsenstein K.M., Hunihan L.W., and Roberts S.B. Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation. Nat Genet 6 3 (1994) 251-255
37. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci 695 (1993) 144-148
38. Jarrett J.T., and Lansbury Jr. P.T. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73 6 (1993) 1055-1058
39. Jarrett J.T., Berger E.P., and Lansbury Jr. P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 18 (1993) 4693-4697
40. Scheuner D., Eckman C., Jensen M., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 8 (1996) 864-870
41. Xia W., Zhang J., Perez R., Koo E.H., and Selkoe D.J. Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci U S A 94 15 (1997) 8208-8213
42. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38 1 (Apr 10 2003) 9-12
43. Martoglio B., and Golde T.E. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. Hum Mol Genet (Oct 15 2003) 12 Spec No 2:R201-6
44. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., and Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. [see comments]. Nature 398 6727 (1999) 513-517
45. McGowan E., Pickford F., Kim J., et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47 2 (Jul 21 2005) 191-199
46. Funato H., Yoshimura M., Kusui K., et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152 6 (Jun 1998) 1633-1640
47. Morishima-Kawashima M., Oshima N., Ogata H., et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 157 6 (Dec 2000) 2093-2099
48. Scheuner D., Eckman C., Jensen M., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. [see comments]. Nat Med 2 8 (1996) 864-870
49. Borchelt D.R., Thinakaran G., Eckman C.B., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 5 (1996) 1005-1013
50. Citron M., Westaway D., Xia W., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3 1 (Jan 1997) 67-72
51. Blessed G., Tomlinson B.E., and Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114 512 (Jul 1968) 797-811
52. McKee A.C., Kosik K.S., and Kowall N.W. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 30 2 (1991) 156-165
53. Nagy Z., Esiri M.M., Jobst K.A., et al. The effects of additional pathology on the cognitive deficit in Alzheimer disease. J Neuropathol Exp Neurol 56 2 (Feb 1997) 165-170
54. Cummings B.J., Pike C.J., Shankle R., and Cotman C.W. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. [see comments]. Neurobiol Aging 17 6 (1996) 921-933
55. Davis D.G., Schmitt F.A., Wekstein D.R., and Markesbery W.R. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58 4 (Apr 1999) 376-388
56. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 4978 (1990) 279-282
57. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13 4 (Apr 1993) 1676-1687
58. Pike C.J., Walencewicz A.J., Glabe C.G., and Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563 1-2 (1991) 311-314
59. Geula C., Wu C.K., Saroff D., Lorenzo A., Yuan M., and Yankner B.A. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. [see comments]. Nat Med 4 7 (1998) 827-831
60. Frautschy S.A., Baird A., and Cole G.M. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A 88 19 (Oct 1 1991) 8362-8366
61. Kowall N.W., Beal M.F., Busciglio J., Duffy L.K., and Yankner B.A. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 88 16 (Aug 15 1991) 7247-7251
62. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., and Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272 35 (1997) 22364-22372
63. Klein W.L., Stine Jr. W.B., and Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25 5 (May-Jun 2004) 569-580
64. Lambert M.P., Barlow A.K., Chromy B.A., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95 11 (1998) 6448-6453
65. Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., and Selkoe D.J. Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30 4 (Aug 2002) 552-557
66. Gong Y., Chang L., Viola K.L., et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 100 18 (Sep 2 2003) 10417-10422
67. Walsh D.M., Klyubin I., Fadeeva J.V., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 6880 (Apr 4 2002) 535-539
68. Wang H.W., Pasternak J.F., Kuo H., et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924 2 (Jan 11 2002) 133-140
69. Lue L.F., Kuo Y.M., Roher A.E., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 3 (Sep 1999) 853-862
70. McLean C.A., Cherny R.A., Fraser F.W., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 6 (Dec 1999) 860-866
71. Jacobsen J.S., Wu C.C., Redwine J.M., et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103 13 (Mar 28 2006) 5161-5166
72. Lesne S., Koh M.T., Kotilinek L., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 7082 (Mar 16 2006) 352-357
73. Hsia A.Y., Masliah E., McConlogue L., et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96 6 (Mar 16 1999) 3228-3233
74. Comery T.A., Martone R.L., Aschmies S., et al. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25 39 (Sep 28 2005) 8898-8902
75. Dodart J.C., Bales K.R., Gannon K.S., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5 5 (May 2002) 452-457
76. Kotilinek L.A., Bacskai B., Westerman M., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22 15 (Aug 1 2002) 6331-6335
77. Lee E.B., Leng L.Z., Zhang B., et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281 7 (Feb 17 2006) 4292-4299
78. McLaurin J., Kierstead M.E., Brown M.E., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12 7 (Jul 2006) 801-808
79. Townsend M., Cleary J.P., Mehta T., et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60 6 (Dec 2006) 668-676